Physician profile

Daryl W Mitchell

Obstetrics & Gynecology · Shreveport, LA

NPI 1992783443

$1,319.46

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$186.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $393.13 2019-2023
Lupin INC. $309.70 2019-2021
Duchesnay USA Incorporated $197.24 2019
Amgen INC. $125.00 2023 Evenity
Davol INC. $90.00 2022
Myovant Sciences INC. $79.02 2022
Astellas Pharma US INC $27.88 2023-2024 Veozah
Ethicon US, LLC $27.42 2022
Evofem Biosciences, INC. $27.22 2021
Coopersurgical, INC. $18.53 2021
Therapeuticsmd, INC. $12.40 2019
Amag Pharmaceuticals, INC. $11.92 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daryl W Mitchell

$1,319.46

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/226407/daryl-w-mitchell

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.